Your browser doesn't support javascript.
loading
Innate immune mechanisms of mRNA vaccines.
Verbeke, Rein; Hogan, Michael J; Loré, Karin; Pardi, Norbert.
Afiliação
  • Verbeke R; Ghent Research Group on Nanomedicines, Faculty of Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Department of Biochemistry and Molecular Biology, University of British Columbia, BC V6T 1Z4, Vancouver, Canada. Electronic address: rein.verbeke@ugent.be.
  • Hogan MJ; Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Loré K; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, 171 64 Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Pardi N; Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: pnorbert@pennmedicine.upenn.edu.
Immunity ; 55(11): 1993-2005, 2022 11 08.
Article em En | MEDLINE | ID: mdl-36351374
ABSTRACT
The lipid nanoparticle (LNP)-encapsulated, nucleoside-modified mRNA platform has been used to generate safe and effective vaccines in record time against COVID-19. Here, we review the current understanding of the manner whereby mRNA vaccines induce innate immune activation and how this contributes to protective immunity. We discuss innate immune sensing of mRNA vaccines at the cellular and intracellular levels and consider the contribution of both the mRNA and the LNP components to their immunogenicity. A key message that is emerging from recent observations is that the LNP carrier acts as a powerful adjuvant for this novel vaccine platform. In this context, we highlight important gaps in understanding and discuss how new insight into the mechanisms underlying the effectiveness of mRNA-LNP vaccines may enable tailoring mRNA and carrier molecules to develop vaccines with greater effectiveness and milder adverse events in the future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Immunity Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Immunity Ano de publicação: 2022 Tipo de documento: Article